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ABSTRACT 
KYLE FORD GORDON: CELL PROLIFERATION AND VIABILITY 
INHIBITION BY RESVERATROL ON BREAST CANCER CELL LINES 




 Antioxidants are well-known for their various health benefits. They are able to 
protect cells from being damaged by free radicals that are produced by vital biochemical 
processes. It has long been known that antioxidants are important in our everyday health, 
but their potential as disease preventers and potential therapeutic agents is a relatively 
new field of study. Resveratrol, a natural polyphenol and well-known antioxidant, is 
found in plants, fruits, and products derived from them, like red wine. Resveratrol has 
been shown to have various properties, including antiaging, anti-aggregation of platelets, 
anti-inflammatory, and anticancer activities. Because of their many health benefits, 
antioxidants have become a hot topic in cancer research. Oxidative stress, which occurs 
when there is an imbalance between reactive oxygen species (ROS) and antioxidants, has 
been shown to be a potential cause of cancer development. Our research group tested the 
effects of resveratrol, vitamins C and E, and the green tea catechin, epigallocatechin 
gallate (EGCG), on various breast cancer cell lines, though this review will focus on the 
chemotherapeutic potential of resveratrol. In the experiments, breast cancer MCF-7, 
MDA-MB-231, BOM 231, and MCF-7-BOM cell lines were treated with various 
concentrations of resveratrol. A Sulforhodamine B viability assay was used to assess the 
percent inhibition of resveratrol on each cell line. The experiments showed that 
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Introduction: Breast Cancer 
Cancer has become a major health problem across the globe. It is now the second 
leading cause of death in the United States. The American Cancer Society expects cancer 
to kill over 600,000 people in 2019 (27). Cancer is not only widespread but it is an 
extremely variable disease, as the National Cancer Institute recognizes over 100 different 
types of cancer. Cancer is a ruthless disease that takes advantage of a vital life process. 
The human body is made of trillions of cells. As old cells die, new ones divide and take 
their place. Cancer begins to take form when a buildup of cellular mutations cause some 
of these cells to become abnormal and divide uncontrollably. According to the World 
Health Organization, breast cancer is the most common form of cancer in the world 
(other than skin cancer), with over two million cases reported in 2018 (6). Most breast 
cancer occurs in women, with the number of cases in women occurring at a rate 100-
times greater than in men (24). Like all cancers, breast cancer is an extremely complex 
and heterogeneous disease. Despite the variability of breast cancer, great strides have 
been made to identify risk factors that could lead to the development of breast cancer. 
Breast cancer associated gene 1 and 2 (BRCA1 and BRCA2) are two of the most well-
known risk factors for breast cancer at the genomic level. These genes encode tumor 
suppressor proteins, which help to combat tumor growth when functioning properly. 
However, genetics are not solely responsible for the development of breast cancer. 
Aging, hormone levels, lifestyle, and gender can also greatly influence the development 
of breast cancer. Despite the high incidence of breast cancer, there have been new 
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developments in recent years to combat this disease. This is because of new therapies, 
early detection, and knowledge about the prevention of breast cancer. 
The breasts are a very complex and important part of human anatomy. Breast 
tissue undergoes many changes during the course of a lifetime. From birth to the end of 
menopause they are constantly growing and their cells are dividing. After puberty, breast 
tissue undergoes even greater changes during breastfeeding and menopause. These 
changes are necessary to breastfeed children, but they also create an opportunity for 
cancer to manifest. Cancer results from the buildup of mutations over time, which are 
more common in tissues that have cells which divide often. Breast tissue contains 
approximately 20 lobes which contain smaller lobules that are responsible for producing 
milk. The lobules are able to move this milk to the nipple through tubes called ducts. 
Breast cancer typically begins in these ducts (ductal carcinoma) or in the lobules (lobular 
carcinoma) (2). 
 Breast cancer can form as a result of genetic pre-dispositions, environmental 
factors, or a combination of both. Every person has a unique set of DNA that codes for 
the human body and all of its processes. Genes are small sections of this DNA that code 
for individual traits and provide variability in a population. Every person has two copies 
of each gene: one from each parent. If one parent has a mutation in a certain gene, their 
child has a high chance of inheriting that gene. Recent advances in DNA technology have 
allowed researchers to gain a much better understanding of genetic involvement in 
cancer. Oncogenes and tumor suppressor genes are thought to be two of the biggest 
genetic players in the development of cancer. Oncogenes are mutated genes that have the 
potential to become cancerous, while tumor suppressor genes are responsible for tumor 
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repression. Just as the name suggests, a loss in function in a tumor suppressor gene can 
allow for tumor growth. Most inherited cases of breast cancer involve the genes BRCA1 
or BRCA2. When these genes are not functioning properly, the risk for developing breast 
or ovarian cancer increases significantly. The BRCA1 and BRCA2 mutations account for 
approximately 10% of all breast cancer cases (29). Approximately 50% of women with 
either the BRCA1 or BRCA2 gene mutation will develop breast cancer at some point in 
their life (1). Various BRCA1 mutations can lead to dysregulation of the cell cycle, 
genetic instability, and eventually, apoptosis. The proteins encoded by BRCA2 regulate 
chromosomal breaks and repairs. If an individual inherits a deleterious BRCA1/2 gene, 
their risk for breast cancer increases dramatically. These genes are inherited in an 
autosomal dominant fashion, so only one mutated allele is necessary for deleterious 
effects to appear (24).  
Human epidermal growth factor receptor 2 (HER2) overexpression increases the 
number of cancer stem cells and is found in approximately 20% of primary breast cancers 
(24). Functioning as a tyrosine kinase, HER2 protein overexpression can lead to 
uncontrolled cell growth. Additionally, tumor cells that present high levels of HER2 have 
a poorer prognosis (15). Epidermal growth factor receptor (EGFR), also known as HER1, 
is a cell surface protein that promotes cell proliferation, invasion, angiogenesis, and 
apoptosis prevention. Patients with tumors that at are EGFR-positive have a much poorer 
prognosis than EGFR-negative patients (24). Furthermore, more than half of patients with 
triple-negative breast cancer (TNBC), the deadliest form of breast cancer, have EGFR 
overexpression. Estrogens (ERs) are sex hormones that promote the development and 
maintenance of the female sex characteristics. They are one of the most prominent 
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players in breast cancer because of their cell proliferating and growth stimulating 
capabilities. Estrogens are essential to the development of the lobes in the female breast, 
but they can promote breast cancer if they are present at high levels. In fact, in ER+ 
breast cancer patients, the concentration of estrogen in breast tissue has been shown to be 
20-times higher than in normal breast tissue (18). Thus, a common treatment for breast 
cancer patients is to block estrogen from binding to its receptor through hormone therapy. 
There are two types of ERs that have different physiological roles; ERa and ERb. 
Phytoestrogens, such as resveratrol, are found in plants and have been linked to a 
decrease in risk for developing breast cancer. Resveratrol is able to mitigate the cell 
proliferating capabilities of both subtypes of ERs but was shown to promote cell growth 
in in late stage cancer cells that lack ERb (18). 
 Environmental risk factors for developing breast cancer range from lifestyle to 
aging. Aging, as it is in all cancers, is perhaps the biggest determinant in the development 
of breast cancer. Interestingly, the median age for the development of breast cancer varies 
with ethnicity. For example, according to the National Cancer Society, the median age of 
a breast cancer diagnosis for white women is 63, while that for African American women 
is 59 (3). Therefore, it is advised that women over the age of 40 have a mammography 
screening. Reproductive factors such as early menarche (first menstruation), late child 
bearing, low parity (number of child births), and late menopause can all increase the risk 
of developing breast cancer. Multiple successful pregnancies have been shown to 
decrease the risk of developing breast cancer after the age of 40 regardless of the age at 
first birth, but increases the risk for breast cancer diagnosis before 40 years of age (3). 
The relationship between reproductive factors and breast cancer development is very 
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complex, but a trend has emerged between certain factors and the development of 
estrogen/progesterone (ER/PR) positive or negative tumors. Both natural estrogen 
production and exogenous estrogen consumption are associated with breast cancer risk. 
Estrogen plays an important role in premenopausal women, but an ovariectomy can be 
performed to reduce the risk of breast cancer development in older women. Exogenous 
estrogen commonly comes in the form of oral contraceptives and hormone replacement 
therapy (HRT). Research suggests that oral contraceptives are more strongly associated 
with ER-negative tumors than ER-positive tumors, though the side effects of oral 
contraceptives has been greatly reduced since their original production. Women who stop 
using oral contraceptives for more than 10 years can completely eliminate their risk of 
developing breast cancer from exogenous estrogen. Additionally, studies have shown that 
the use of HRT can increase the risk of developing breast cancer. The Million Women 
Study in UK showed that women who currently take HRT have a relative risk (RR) of 
1.66 for developing breast cancer when compared to those who have never used HRT 
(24). In 2003, the Women’s Health Initiative published data reflecting the negative 
effects of HRT. Since then, the incidence rate of breast cancer caused by HRT has 
dropped 7% (24).  
 Unhealthy eating and drinking habits can also increase one’s risk of developing 
breast cancer. It is recognized that early-life exposure to carcinogens can increase a 
women’s lifetime risk of breast cancer. Breast cancer risk builds over the course of a 
lifetime, but research suggests that the majority of the buildup occurs between menarche 
and first pregnancy. There appears to be a critical period after the onset of menarche, 
when breast tissue is growing and dividing rapidly, all the way until the first pregnancy. 
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Thus alcohol, which is a breast carcinogen, if consumed early in life, could contribute to 
increased breast cancer risk. Specifically, daily excessive alcohol consumption can 
increase the risk of breast cancer by 32% (24). Case-control studies showed that alcohol 
consumption (1 drink/day) before the age of 30 increased the risk of premenopausal 
breast cancer by 34% (13). However, in the same study it was shown that alcohol 
consumption before the age of 30 did not affect postmenopausal women. This is further 
evidence that a critical period could exist in breast cancer development. Eating a healthy 
diet alone is not enough to prevent breast cancer, but it can contribute to lowering one’s 
risk for developing it. Several vitamins and natural phenols have been identified as 
potential substances that can help to fight and or treat breast cancer. Resveratrol, a natural 
phenol, will be discussed later in this paper.  
The development of breast cancer does not happen in one step, it is a multifaceted 
disease that takes time to develop. Some stages are much less dangerous than others, so 
doctors need a way to describe which stage a tumor is in at a certain time. In order to do 
this, doctors use a tumor, node, and metastasis (TNM) staging system (4). The following 
stages have been created to show tumor progression: normal epithelial cells, hyperplasia, 
hyperplasia with atypia, and carcinoma in situ invasive cancer. Typically, breast cancer 
begins in the milk-producing ducts of the breast. Often considered stage 0, ductal 
carcinoma in situ is a type of non-invasive breast cancer. It is characterized by the 
development of abnormal epithelial cells lining the milk ducts of the breast. While this 
stage is not considered life-threatening, treatment is still recommended to prevent further 
growth and spreading. In stage 1 breast cancer, the tumor is less than two cm in size, but 
the cancer is now considered invasive. The tumor has not spread to other parts of the 
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body at this point and successful treatment is still very likely. Even though stage 1 is not 
considered life threatening, treatment usually immediately follows a diagnosis. Stage 1 
breast cancer is highly treatable, with radiation and/or surgery being the two most 
common treatment plans (20). In addition to radiation and surgery, a person with stage 1 
breast cancer could also consider hormone therapy. Hormone therapy for breast cancer 
can be very effective if the particular type of breast cancer is sensitive to hormones. It 
works by blocking a hormone from attaching to its receptor or by blocking hormone 
production, thus blocking the function of the hormone (11). Stage 2 breast cancer is 
characterized by increased tumor growth, but the tumor is still contained in the breasts or 
nearby lymph nodes. Stage 2 is further divided in two groups: A and B. Stage 2A breast 
cancer can be applied to three different scenarios. The first scenario includes no tumor 
present but cancer cells have spread to the lymph nodes. The second scenario is that the 
tumor is less than two cm in size and has spread to the lymph nodes. Finally, the tumor 
has to be two to five cm in size and have not spread to the lymph nodes to be included in 
stage 2A. Stage 2B breast cancer is defined by 2 different situations. If the tumor is 2-5 
cm in size and has spread to less than four nearby lymph nodes, then it is in stage 2B. 
Additionally, if the tumor grows to be larger than five cm, but has not spread to any 
lymph nodes, then it is in stage 2B (22) 
 Stage 3 breast cancer means the cancer has spread beyond the primary tumor site 
and may have invaded nearby tissues, but has not spread to distant organs. Stage 3 breast 
cancer is divided in to 3 groups: 3A, 3B, and 3C. The difference between stages is 
determined by the size of the tumor and whether the cancer has spread to the lymph 
nodes and surrounding tissue. Although stage 3 breast cancer is considered advanced, 
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there is a growing number of treatment options available. Stage 3 treatment options 
include mastectomy, radiation, hormone therapy, and chemotherapy. A combination of 2 
or more treatments is typically the most effective for this stage (21). Stage 4 breast cancer 
means that the cancer has spread to other parts of the body, such as the brain, bones, 
lungs, and liver. Stage 4 breast cancer is considered incurable, but new treatments have 
prolonged the lives of stage 4 breast cancer patients (19). During this stage of cancer, 
patients can be exposed to experimental treatments if they are willing. 
 
Tumor Formation: 
Reactive oxygen species (ROS) consist of radical and non-radical oxygen species 
that have partially reduced oxygen molecules. These ROS are important regulators of 
homeostasis in moderate concentrations, but can become a major health problem if 
present in high concentration (7). Much of cellular ROS production is a by-product of 
oxidative phosphorylation occurring in the mitochondria but ROS can also be produced 
during an immune response to foreign substances. Oxidative stress can occur when there 
is an imbalance between the concentration of ROS and an antioxidant response. 
Oxidative stress caused by ROS has been shown to damage nucleic acids, proteins, and 
lipids (7). Additionally, ROS have the ability to promote disease formation (such as 
cancer) through signaling pathways. For example, ROS have been shown to promote cell 
proliferation, survival, and differentiation by activating the PI3K pathway. However, 
ROS have also been shown to induce apoptosis and cellular aging in certain cell lines. 
Therefore, how a cell reacts to ROS depends on its molecular background and 
surrounding environment. At high concentration, ROS can cause apoptosis in cancer cells 
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due to cellular damage. However, ROS plays a much larger role in signal transduction in 
tumor formation, progression, and survival. 
 Many cancers form solid masses of tissue called tumors after a period of time. 
The word tumor has a Latin origin that translates to “swelling” in English but not all 
swellings can be considered tumors. Wallace H. Clark, a celebrated pathologist, defined 
tumors as meeting the following criteria; they consist of cells experiencing temporally 
unrestricted growth, and the ability to grow in at least three different tissue 
compartments. Included in these compartments are the original site, the mesenchyme of 
the primary site, and the mesenchyme of a distant site. This definition of a tumor 
encompasses the benign beginning, invasive nature, and potential to spread that tumors 
have. Tumors consist of two separate but interdependent compartments. The parenchyma 
consists of neoplastic cells that exhibit uncontrolled growth. The other compartment, the 
stroma, consists of the connective tissue, blood vessels, and other components that keep 
the tumor alive and allow it to grow. All tumors that grow beyond one to two mm in size 
require stroma for survival. Tumor stroma is formed from circulating components of the 
blood. These elements are able to enter tissues in areas that consist of high levels of 
vascular endothelial growth factor (VEGF-A), which promotes high vascular 
permeability. The angiogenic growth factor, VEGF-A, is the most studied and well 
known in a family of proteins that also consists of vascular endothelial growth factors B, 
C, D, and E. Additionally, VEGF-A acts as a cytokine that serves many functions and is 
produced by both animals and humans. Among its many other activities, VEGF-A plays a 
large part in the immune response. Its vascular permeability inducing activity facilitates 
elements from the blood to enter wound sites and aid in the healing process. However, 
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VEGF-A plays a monumental role in the development of cancer. In addition to its role in 
stroma formation, VEGF-A contributes greatly to angiogenesis (the formation of new 
blood vessels) by binding to and activating vascular endothelial growth factor receptors 
(VEGFR). Upon VEGF binding to VEGFR, a tyrosine kinase cascade is activated, 
signaling new blood vessels to form. These new blood vessels are not the same as 
healthy, normal blood vessels. They are often leaky, disorganized, and have irregular 
blood flow. Further, VEGF-A plays a critical role in embryonic development and wound-
healing in adults. However, VEGF-A is overexpressed in cancerous cells causing a large 
increase in angiogenesis, which is a hallmark of cancer.  
The heterodimeric transcription factor hypoxia-inducible factor-1 (HIF-1), is the 
primary activator of VEGF-A (17). Under normoxic conditions, its hypoxia-regulated 
HIF-1α subunit is proteolytically degraded very quickly, with a physiological half-life of 
about five minutes. In the presence of oxygen, divalent iron ions bind to the proline or 
asparagine residues of HIF-1α and promote is rapid proteolysis. However, HIF-1α is 
stable and present in high levels in hypoxic environments, where it heterodimerizes with 
the constitutively expressed HIF-1β subunit, and activates the herterodimeric 
transcription factor complex known as HIF-1. Because of the irregularities of tumor 
vasculature, the tumor microenvironment is typically hypoxic, which leads to an increase 
in oncogene expression of HIF-1α. When activated by HIF-1, VEGF-A promotes tumor 
angiogenesis. Tumors are able to grow in size with the development of new blood vessels 
that feed the tumor. Thus, tumors are able to take advantage of the hypoxic environment 
that their vasculature creates in order to grow and survive. 
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 The transcription factor HIF-1 also has a prominent role in the regulation of 
oxidative phosphorylation and ROS production. When ROS are present in high levels, 
HIF-1 can suppress ROS formation by inhibiting the mitochondrial tricarboxylic acid 
cycle. Low concentrations of ROS can trigger HIF-1 to increase ROS formation through 
NADPH oxidase (7). In healthy cells, ROS formation is a byproduct of oxidative 
phosphorylation and is present in minimal concentrations due to antioxidant systems. 
When these systems fail and ROS concentrations rise, oxidative damage can follow. 
Additionally, ROS have been shown to stabilize HIF-1α, which leads to HIF-1α 
accumulation and subsequent HIF-1 activation. Therefore, it is possible that ROS play a 
major role in tumor angiogenesis by stabilizing HIF-1α. 
 
Metastasis: 
 One of the major issues with cancer is its ability to spread to other parts of the 
body. In a process called metastasis, cancer can spread locally into nearby tissues or to 
distant parts of the body through the circulatory or lymphatic systems. Nearly all types of 
cancer have the potential to become metastatic (6). Individual and environmental factors 
determine whether or not the cancer will become metastatic. There are three common 
ways metastasis can occur: by growing directly into tissue surrounding the tumor, 
traveling through the bloodstream, or by traveling through the lymphatic system. 
Metastasis is composed of several steps that leads to the spread of cancer throughout the 
body in a process known as the metastatic cascade. Metastasis begins when cancer cells 
detach from the primary tumor site in a process called invasion (25). The route of the 
detached cancer cell depends on the location of the primary tumor. For example, a breast 
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cancer tumor undergoing metastasis has the potential to invade the lungs, brain, lymph 
nodes, or liver. Many factors can contribute to cell detachment, including tumor growth, 
necrosis, and enzyme activity. Cancer cells can undergo an epithelial-mesenchymal 
transition (EMT) to gain migratory abilities. The process of EMT can be initiated by 
signaling from growth factors such as TGF-b or from cell proliferation proteins such as 
Wnt (25). Initiating EMT increases the expression of EMT transcription factors that are 
involved with the downregulation of epithelial cadherins (proteins that promote cell-cell 
binding). Many studies have shown that ROS are major activators of EMT by acting as 
secondary messengers. The growth factor, TGF-b, regulates urokinase type plasminogen 
activator (uPA) and matrix metallopeptidase 9 (MMP-9) through an ROS mechanism 
(12). This results in a weaker bond between cancer cells and the tumor, promoting 
detachment and leading to an increase in cell-stroma interactions (25). After a cancer cell 
detaches from the primary tumor, it begins a perilous journey around the body. 
Intravasation is the process by which cancer cells enter the circulatory system 
through blood or lymphatic vessels. These circulating tumor cells (CTCs) are often killed 
by stress or the immune system, or they can become lodged in a capillary bed where they 
form a new tumor. This circulation process is very inefficient, with only 0.01% of CTCs 
actually forming a distant tumor (8). However, it is very important to study and 
understand intravasation because it is a major part of the deadly metastatic cascade. The 
content of the tumor microenvironment, proteases, and signaling molecules all play a part 
in the process of intravasation. Angiogenesis is the process by which new blood vessels 
form, so it follows that tumors with a higher degree of angiogenesis could also 
experience higher levels of intravasation. As mentioned earlier, VEGF-A plays a large 
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part in increasing vascular permeability and blood vessel formation. Additionally, VEGF-
A leads to an increase in microvessel density, which has been linked to an increase in 
intravasation (8). The primary activator of VEGF-A, HIF-1, is also an activator of 
proteases known as matrix metalloproteinases (MMPs). These zinc-dependent 
endopeptidases are responsible for the breakdown of the extracellular matrix (ECM), 
which serves as the physical barrier between tumor cells and blood and lymphatic 
vessels. Once cancer cells are able to enter into the circulatory system, they have the 
potential to invade other parts of the body. If these cells are able to establish themselves 
in other tissues, the result is often lethal.  
Extravasation is the process by which CTCs exit the circulatory system to form 
secondary tumors. Once CTCs are in their new location, they go through a mesenchymal-
epithelial transition (MET) to form a new tumor. Extravasation is a very dynamic process 
and is not as well understood as the previous steps of the metastatic cascade. However, 
further research should be conducted on this process because of its potential as a target 
for anti-metastatic drugs. 
 
Treatment:  
 Breast cancer is the deadliest form of cancer among women in the world (18). It is 
more prevalent in developed countries, but the mortality rates are much higher in poorer 
countries because of fewer and inferior treatment options. The high incidence of breast 
cancer has made it become one of the most widely studied forms of cancer. Early 
detection in the form of biomarkers has served as a huge step towards curing breast 
cancer. Estrogen (ER) and progesterone (PR) receptors have been the most widely 
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studied biomarkers for early breast cancer detection and prevention. Additionally, 
advances in DNA technology have allowed researchers to target early breast cancer 
detection at the level of DNA processing. However, thousands of people still die from 
breast cancer every year and countless more suffer from a lower quality of life from the 
side effects of the toxic drugs that they have to take to survive. The most common form 
of treatment for metastatic breast cancer is surgery, but almost all treatment plans use a 
combination of therapies. Radiotherapy, chemotherapy, and immune therapy are also 
common treatment options. Resistance to therapies and high toxicity of primary treatment 
options have led researchers to look in to more natural options for breast cancer 
treatment. Phytochemicals, a large family of bioactive compounds found in plants, have 
emerged as leading candidates for the management and prevention of breast cancer (18). 
Several phytochemicals have been shown to induce apoptosis in breast cancer cells and 
prevent the growth of tumors by inhibiting angiogenesis, causing DNA damage through 
oxidative stress, controlling proliferation, and overtaking cell signaling pathways. In this 
review, breast cancer cell lines were treated with resveratrol, a non-flavonoid polyphenol. 
 Resveratrol (trans-3,4′,5-trihydroxystilbene, C14H12O3) is a naturally occurring 
polyphenol that is present in grapes, berries, peanuts, soy beans, and certain fungi (18). 
Resveratrol is thought to have beneficial effects on the human heart. The French consume 
a high amount of red wine, which is rich in saturated fat, yet they have few heart related 
problems. This “French Paradox” is thought to be related to the beneficial effects of 
resveratrol. Additionally, resveratrol has been shown to have various benefits in 
coronary, neurological, hepatic, and cardiovascular systems (18). It has been shown to 
fight inflammation, reduce reactive oxygen species, freeze the cell cycle, restore 
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apoptosis, and slow cancer cell growth in various cell lines. Mitochondrial Complex I 
releases superoxide radicals into the mitochondrial matrix, where mitochondrial 
manganese SOD (SOD2) converts the superoxide radicals to hydrogen peroxide. Next, 
hydrogen peroxide is converted to water by glutathione peroxidases (GSH). Resveratrol 
has been shown to be a scavenger of certain oxidants including superoxide radicals and 
hydrogen peroxide. However, resveratrol is only effective at scavenging low levels of 
ROS. Instead, resveratrol’s best antioxidant properties work at the level of DNA 
transcription (28).  
 
Figure 1. Resveratrol Structure. This image was created using ChemDoodle3D.  
  
 Interestingly, resveratrol has been shown to have prooxidative and antioxidative 
properties. Resveratrol is well-known as an antioxidant, but it can act as a prooxidant in 
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the presence of certain transition metals such as copper (18). As described earlier, ROS 
are able to damage macromolecules such as DNA when present in high concentrations. If 
ROS could be contained to a tumor site, then ROS generation could potentially be an 
avenue for cancer treatment by damaging DNA and preventing cell growth and 
proliferation. On the other hand, resveratrol is known to be a scavenger of ROS. It is able 
to stabilize free radicals by forming a resonance-stabilized peroxyl radical, thus 
diminishing the effects of ROS. In this way, resveratrol is preventing the accumulation of 
ROS, which can lead to cancer by damaging healthy DNA. Resveratrol is also involved 
with an increase in antioxidant enzymes, such as superoxide dismutase (SOD). The 
antioxidant properties of resveratrol have also been shown to have a synergistic effect 
when combined with certain chemotherapeutic agents. Many chemotherapeutic drugs 
work through a pro-oxidant mechanism, leading to a buildup of ROS that can cause 
toxicity in the body. In one study, Resveratrol protected against cardiotoxicity in H9c2 
cardiomyocytes that were treated with doxorubicin by blocking ROS production through 
the upregulation of manganese superoxide dismutase (18). This review focuses on the 
antioxidant properties of resveratrol. 
Cancer stem cells (CSCs) are cancer cells that have similar properties to normal 
stem cells, specifically the ability to become any cell type found in the body. Cancer stem 
cell theory has gained much traction over recent years. This theory suggests that there is a 
small subpopulation of cells within the tumor that are responsible for the persistence of 
the disease. Other cells can still cause problems, but the CSCs are the root of the issue 
according to this theory (23). Cancer stem cell theory suggests that if the CSCs are not 
destroyed but the signs of cancer have been eliminated, then the cancer will grow back. 
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Most chemotherapies and radiotherapies do not target CSCs. Thus, many new anticancer 
drugs are now focusing on this small subpopulation of cells to combat tumor growth. 
These drugs could work by re-sensitizing CSCs to chemotherapy drugs or blocking self-
renewal pathways. In a number of studies, resveratrol has been shown to slow or halt the 
differentiation of the CSCs directly and indirectly (18).  
 Adjuvant therapy is treatment that is given in addition to the primary treatment 
(surgery, chemotherapy, etc.) Phytochemicals, such as resveratrol, have proven to be one 
of the most effective adjuvant treatment drugs. These compounds are able to reverse drug 
resistance in some tumors and increase sensitivity to drugs in others. Resveratrol has been 
shown to increase the antitumor activities of drugs such as doxorubicin, which belongs to 
the class of chemotherapy drugs known as anthracyclines. Anthracyclines inhibit 
topoisomerase 2, which cells need to divide and grow. Resveratrol, when combined with 
doxorubicin, has been able to increase the power of doxorubicin without affecting normal 
cells. Carbonyl reductase 1 (CBR1) catalyzes the reaction of doxorubicin to 
doxorubicinol, which causes cardiotoxicity and diminishes the antitumor potential of 
doxorubicin. If CBR1 is present in high levels, chemoresistance of tumor cells is 
enhanced. Resveratrol has the ability to bind to CBR1, thus re-sensitizing cancer cells to 
doxorubicin. A case control study performed from 1993-2003 examined the effect of 
resveratrol intake in breast cancer patients. There were 369 patients that were given 
resveratrol, and 602 patients that were not. The study showed that breast cancer risk was 
decreased in the patients taking resveratrol (18).  
 In the experiments performed by the research group, we studied the effects of 
resveratrol, vitamins C and E, and epigallocatechin gallate (EGCG) on several breast 
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cancer cell lines. This review will focus on the antioxidant therapeutic capabilities of 
resveratrol.  
 
Natural Product Studies: 
 The research team began working in the spring of 2019 and conducted research 
under the direction of Dr. Zhou and Dr. Nagle until spring 2020. We began with literature 
research into breast cancer to gain a better understanding of the mechanisms underlying 
this complicated disease. After deciding to pursue research regarding the effects of 
certain compounds on breast cancer cell lines, Dr. Zhou advised us to find a less studied 
compound to increase the originality. While it is difficult to be completely original in this 
field, background research increased our knowledge of the field and helped us select a 
topic. Literature review showed us that resveratrol has been studied in various ways over 
the past decade. For example, resveratrol has been shown to have positive effects on the 
heart, kidneys, and cancer patients (18). After selecting a compound to study, a plan was 
created to study the effects of resveratrol, vitamins C and E, and EGCG on various breast 
cancer cell lines. The chemotherapeutic experiment consisted of literature research, cell 
culture procedures, and a viability assay. Experiments were concluded in November 2019 
and the data analysis and writing process began soon after. Our general hypothesis stated 
that these compounds (resveratrol, vitamins C and E, EGCG) would cause damage to 
certain breast cancer cell lines or inhibit their growth.  
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Materials and Methods: 
 
Sulforhodamine B (SRB) Viability Assay:  
 The Sulforhodamine B (SRB) assay is a widely used method to determine 
cytotoxicity in cell-based studies in a relatively inexpensive and efficient manner (16). 
Sulforhodamine B is a fluorescent dye that binds to proteins under acidic conditions and 
can be used to determine cell inhibition/apoptosis. This assay was used after the cells 
were seeded in a 96-well plate with a cell density of 30,000 cells/well and 100 mL/well 
of media. First, cells were trypsonized with 1.0 mL Trypsin. This step was performed to 
prevent cell-cell attachment. Next, the cells were washed with 10 mL of 10% fetal bovine 
serum (FBS) media. Then, the plates were cultured at 37° C for 24 hours. After 24 hours, 
test compounds diluted in serum-free RPMI 1640 media with L-glutamine (2 mM), 
penicillin, and streptomycin were added (100 mL/well.) The compounds were prepared 
as stock solutions in DMSO with a final concentration of 0.25% (v/v).  After 48 hours, 
100 µL of media was removed from each well. 100 µL of 20 % trichloroacetic acid 
(TCA) in 1x PBS solution were then added to each well to begin the staining process. 
The wells were then incubated at 4° C for 1 hour. Next, the wells were washed with tap 
water and then stained with 100 µL of 0.4% SRB (w/v, 1% acetic acid). The plates were 
then washed 4 times with 1% acetic acid and allowed to dry. Then, Tris Base (100 µL of 
10 mM) was added to each well at a volume of 200 mL/well. The wells were shaken for 
10 minutes and were then ready to be analyzed using the SpectaFluor plate and Magellan 
software. The absorbance range was set to 496-620 nm. The Magellan software was able 
to calculate the inhibition value by analyzing the total protein mass density in each well. 
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Cell viability data is presented as percent control using the formula: % Control = 
(ODcompound/ODcontrol) x 100.  
 
 MCF-7 BOM MD-MBA-231 MCF-7-BOM 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Media Control 100 µL (negative control)  
B Media Control 100 µL (negative control)  
C 1 µM Resveratrol 
D 10 µM Resveratrol 
E 30 µM Resveratrol 
F 100 µM Resveratrol 
G 300 µM Resveratrol 
H 10 µM Cycloheximide (positive control)  
 
Figure 2. Resveratrol Concentrations in 96-Well Plate Layout  
 
 
Natural Product Dilution Plate 
 The chemotherapeutic agents were purchased from Sigma Aldrich or The 
Association of Clinical Research Organizations (ACRO). For this experiment, we set the 
stock solution concentration at a range from 1 µM to 300 µM for each compound. DMSO 
was added to each chemotherapeutic agent to acquire the desired stock concentration for 
the experiment. Fetal bovine serum (FBS) was used as media to dilute the stock solutions 
to the highest tested concentration. A 1:10 serial dilution was performed in a stepwise 
manner as can be seen in the table below.  
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Resveratrol solution Stock Dilution Media Volume  
300 µM 50.4 µL of 50 µM 4.15 mL  
100 µM 1.1 mL of 300 µM 2.2 mL  
30 µM 330 µL of 300 µM 2.97 mL  
10 µM  330 µL of 100 µM 2970 mL  
1 µM 300 µL of 10 µM 2700 mL 
 
Figure 3. Serial Dilution of Resveratrol 
 
Cell Lines: 
 Four cancer cell lines were used in this experiment: MCF-7, BOM 231, MDA-
MB-231, and MCF-7-BOM. The MCF-7 is a human breast cancer cell line with estrogen, 
progesterone, and glucocorticoid receptors (5). It was derived from a 69-year old 
Caucasian woman with adenocarcinoma in 1970 by Dr. Herbert Soule. MCF-7 is very 
useful for in vitro studies because of its ability to process estrogen as an in vivo breast 
cancer cell would. The MDA-MB-231 cell line is a triple-negative breast cancer cell line 
that was derived from a 51-year-old Caucasian female with invasive ductal carcinoma in 
1970 (26). This cell line is highly aggressive, invasive and lacks estrogen and 
progesterone receptors, and does not overexpress HER2. Additionally, this cell line has a 
mutated p53 (tumor suppressor) gene. MDA-MB-231 cells are invasive when implanted 
and metastasize to lymph nodes in vivo. This cell line also commonly metastasizes to the 
lung and bone to form secondary tumors. The BOM 231 is a cell line from metastatic 
bone cancer that was derived from the secondary tumors of MDA-MB-231. The BOM 
231 cell line was generated in Dr. J. Massagúe’s lab at Memorial Sloan Kettering Cancer 
Center, New York City, New York. The specific BOM 231 cell line that we used was 
acquired from Dr. Konosuke Watabe at Wake Forest University. The MCF-7 BOM is 
also a metastatic bone cancer cell line that was derived from secondary tumors formed by 
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the breast cancer cell line MCF-7. The MCF-7-BOM was also generated in Dr. J. 
Massagúe’s lab at Memorial Sloan Kettering Cancer Center, New York City, New York. 
We acquired MCF-7-BOM cells from Dr. Konosuke Watabe at Wake Forest University.  
 All cell lines were maintained in RPMI 1640 media with L-glutamine (2 mM) 
(Mediatech), supplemented with fetal bovine serum [FBS, 10% (v/v), Hyclone], 
penicillin (50 units/mL), and streptomycin (50 µg/mL) (Lonza) in an atmosphere 




 Figure 4 was created to compare results under normoxic and hypoxic conditions, 
as well as treatment with cycloheximide, which was the positive control in this 
experiment. In all cell lines except for MCF-7-BOM, cell viability and proliferation from 
the media control was reduced under hypoxic conditions compared to normoxic 
conditions. Hypoxic conditions result when there is an absence of oxygen in the 
physiological system, which can lead to stress on a cell because they have to switch to 
anaerobic respiration to produce energy. Anaerobic respiration is not as efficient as 
aerobic respiration, which could lead to cell stress and eventually apoptosis. The graphs 





























































Figure 4. Normoxia, hypoxia, and cycloheximide (CHX) compared to normoxic media 
control. 
 
SRB Viability Assay 
 The results of the Sulforhodamine B viability assay reflect the percent inhibition 
values of resveratrol tested on the cell lines MCF-7, BOM-231, MDA-MB-231, and 
MCF-7-BOM. The goal of this assay was to acquire an IC50 value, which is the drug 
concentration where cell growth is inhibited by 50%. This means that a lower IC50 value 
indicates a more effective drug. However, while each cell line and condition showed 
inhibition, only MCF-7 normoxia and hypoxia, and BOM 231 hypoxia were inhibited 
enough for an IC50 value to be calculated within the highest concentration of resveratrol 
tested. Prism Graphpad 8 was able to calculate an IC50 value for all cell lines, but only 
three of the cell lines fell within the range of concentrations tested. The other cell lines 
had an IC50 value over 300 µM. The following charts reflect percent inhibition of 





















































resveratrol on each cell line that were incubated under either of two conditions: normoxia 
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Discussion 
 From the SRB assay, resveratrol was shown to be capable of inhibiting cell 
proliferation in a concentration and cell line dependent manner. The MCF-7 cell line 
proved to be the most susceptible to resveratrol treatment in both normoxic and hypoxic 
conditions at maximum resveratrol concentration. This cell line also showed an increase 
in % inhibition when the concentration of resveratrol was increased in both conditions. 
The MCF-7 cell line could be the most susceptible because it is an ER+ cell line and 
resveratrol has shown to have phytoestrogen properties. The resveratrol IC50 value was 
the smallest in the MCF-7 normoxia cell line, indicating that this cell line was the most 
susceptible to resveratrol treatment. Resveratrol was also effective at inhibiting the MCF-
7 hypoxia cell line, which produced the second smallest IC50 value. The BOM 231 
hypoxia was the only other cell line that produced an IC50 value that was lower than the 
maximum resveratrol concentration tested. All IC50 values were calculated and fall into a 
95% confidence interval (CI) as shown in Figure 6. These values were calculated using 
prism GraphPad 8. The cell lines that produced IC50 values less than the maximum 
concentration of resveratrol (300 µM) tested are highlighted in green, while those that 
had an IC50 value greater than 300 µM are highlighted in red.  
 
Cell line IC50 (M) 95% CI (M) 
MCF-7 Normoxia 0.0001364 0.000095995 to 0.001 
MCF-7 Hypoxia 0.0001467 .00009323 to 0.001 
BOM 231 Normoxia 0.0003572 0.0002736 to 0.001304 
BOM 231 Hypoxia 0.0002563 0.0001634 to 0.0005 
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MDA-MB-231 Normoxia 0.0003442 0.0001206 to 0.0009 
MDA-MB-231 Hypoxia  0.0004277 0.0002177 to 0.001 
MCF-7 BOM Normoxia  0.001024 0.00009873 to 2.652 
MCF-7 BOM Hypoxia 0.01951 0.0001263 to 3.12 
 
Figure 6. IC50 Values for all Cell Lines 
 
This study was successful in showing that resveratrol is capable of slowing and/or 
inhibiting cell growth in certain breast cancer cell lines. However, the exact mechanism 
of how this occurs is an area that requires further study. One potential area of study could 
be examing resveratrol antioxidant effects in certain cancer cell processes. For example, 
as mentioned earlier, the PI3K pathway relies on ROS to promote cellular proliferation. 
Resveratrol is a known scavenger of ROS and could potentially inhibit this pathway. 
Additonally, the role of resveratrol as a pro-oxidant in breast cancer treatment could be 
an interesting avenue for further research. A major hurdle to this research would be to 





In conclusion, resveratrol was tested on several different cancer cell lines to 
determine its efficacy as a chemotherapeutic compound. Resveratrol proved to be capable 
of inhibiting cell growth and proliferation in cell lines and the results were much more 
profound in specific cell lines. While this study produced results that could lead to 
resveratrol gaining a bigger role as a chemotherapeutic compound, much more research 
needs to be conducted to understand the exact mechanism by which this compound 
works. Additionally, these experiments should be repeated in order to ensure that the data 
provided from this report is accurate. The hypothesis that resveratrol would show cell 
line-dependent inhibition is supported by the percent inhibition data produced from the 
SRB viability assay. The MCF-7 cell line was the most sensitive to resveratrol, possibly 
because of the presence of estrogen receptors in that cell line. However, more 
experiments should be conducted using higher concentrations of resveratrol to acquire 
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